Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
-
Randomized Controlled Trial Comparative Study Clinical Trial
Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
To evaluate the cytoprotective effect of amifostine against radiation-induced acute toxicity to the rectal mucosa. ⋯ Amifostine seems to have a significant cytoprotective efficacy in acute radiation-induced rectal mucositis in terms of symptomatic and objective endpoints.